Daniel P. Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniel P. Costa has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Abraão Pinheiro Sousa
Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS) Department of Chemistry Universidade Federal da Paraíba (UFPB) João Pessoa Brazil
1 shared publication Fernanda S. Almeida
Laboratório de Imunologia das Doenças Infecciosas (LABIDIC), Department of Biology Cellular and Molecular, Federal University of Paraíba, João Pessoa, Brazil
1 shared publication- Gabriela Fehn Fiss
Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS) Department of Chemistry Universidade Federal da Paraíba (UFPB) João Pessoa Brazil
1 shared publication - Leonardo Lima Cardoso
Laboratório de Imunologia das Doenças Infecciosas (LABIDIC), Department of Biology Cellular and Molecular, Federal University of Paraíba, João Pessoa, Brazil
1 shared publication - Marcelo Sobral da Silva
Institute for Research on Drugs and Medicines, Federal University of Paraíba, 58.059-900, João Pessoa, PB, Brazil
1 shared publication - Petrônio Filgueiras De Athayde-Filho
Laboratório de Pesquisa em Bioenergia e Síntese Orgânica (LPBS) Department of Chemistry Universidade Federal da Paraíba (UFPB) João Pessoa Brazil
1 shared publication
Latest Publications
- 1 May 2026
- Published by Bentham Science Publishers Ltd. in Current Organic Chemistry
- Vol. 30 (10) , 734-744
Novel 2-Acetanilide 2-Arylquinoline-4-carboxylates as Antileishmanial Agents: From Prediction to In Vitro Activity/Toxicity
Alarming data on the neglected tropical disease leishmaniasis, especially for global visceral cases, have motivated the development of novel drugs to overcome the emergence of resistance. In this context, quinoline derivatives, especially quinoline-4- carboxylic acids, have shown promising antileishmanial activity. More recently, acetanilide linked quinoline derivatives revealed selective antileishmanial activity. Now, we are motivated to investigate the influence of the substituent group on antileishmanial and toxicity properties of sixteen 2-acetanilide 2-arylquinoline-4-carboxylates. To this end, the precursors, 2-arylquinoline-4-carboxylic acids, prepared from isatin through the Pfitzinger reaction, and 2-chloroacetanilides were used in an alkylation reaction to obtain the final products (5e-t) in yields of 40-88%. Next, 2-acetanilide 2-arylquinoline-4-carboxylates (5e-t) had their in silico/vitro activity evaluated against Leishmania infantum promastigotes. From the MolPredictX program, all compounds were predicted to be active, and only four halogenated compounds (5k, 5n, 5o, 5r) were active by in vitro assays, with the best result for the compound 5n (R/R’ = Br/Cl), IC50 = 17.08 ± 1.09 μM. From the pkCSM program, these compounds were predicted as non-mutagenic, hepatotoxic, and highly cytotoxic on Flathead Minnows. On the other hand, compounds showed moderate ecotoxicity on Artemia salina, with IC50 = 256-297 μg.mL-1. Finally, in contrast of Amphotericin B which caused relevant erythrocyte lysis starting from 50 μM, none of the compounds showed hemolytic activity. Furthermore, compounds were more selective against L. infantum promastigotes than against human erythrocytes, with a selectivity index (HC50/IC50) > 15.63, which demonstrates a promising therapeutic window for 2-acetanilide 2-arylquinoline-4-carboxylates.
- 1 May 2026
- Published by Bentham Science Publishers Ltd. in Current Organic Chemistry
- Vol. 30 (10) , 734-744
Novel 2-Acetanilide 2-Arylquinoline-4-carboxylates as Antileishmanial Agents: From Prediction to In Vitro Activity/Toxicity
Alarming data on the neglected tropical disease leishmaniasis, especially for global visceral cases, have motivated the development of novel drugs to overcome the emergence of resistance. In this context, quinoline derivatives, especially quinoline-4- carboxylic acids, have shown promising antileishmanial activity. More recently, acetanilide linked quinoline derivatives revealed selective antileishmanial activity. Now, we are motivated to investigate the influence of the substituent group on antileishmanial and toxicity properties of sixteen 2-acetanilide 2-arylquinoline-4-carboxylates. To this end, the precursors, 2-arylquinoline-4-carboxylic acids, prepared from isatin through the Pfitzinger reaction, and 2-chloroacetanilides were used in an alkylation reaction to obtain the final products (5e-t) in yields of 40-88%. Next, 2-acetanilide 2-arylquinoline-4-carboxylates (5e-t) had their in silico/vitro activity evaluated against Leishmania infantum promastigotes. From the MolPredictX program, all compounds were predicted to be active, and only four halogenated compounds (5k, 5n, 5o, 5r) were active by in vitro assays, with the best result for the compound 5n (R/R’ = Br/Cl), IC50 = 17.08 ± 1.09 μM. From the pkCSM program, these compounds were predicted as non-mutagenic, hepatotoxic, and highly cytotoxic on Flathead Minnows. On the other hand, compounds showed moderate ecotoxicity on Artemia salina, with IC50 = 256-297 μg.mL-1. Finally, in contrast of Amphotericin B which caused relevant erythrocyte lysis starting from 50 μM, none of the compounds showed hemolytic activity. Furthermore, compounds were more selective against L. infantum promastigotes than against human erythrocytes, with a selectivity index (HC50/IC50) > 15.63, which demonstrates a promising therapeutic window for 2-acetanilide 2-arylquinoline-4-carboxylates.